全文获取类型
收费全文 | 1335211篇 |
免费 | 100196篇 |
国内免费 | 4271篇 |
专业分类
耳鼻咽喉 | 16797篇 |
儿科学 | 43593篇 |
妇产科学 | 36363篇 |
基础医学 | 197823篇 |
口腔科学 | 35902篇 |
临床医学 | 129558篇 |
内科学 | 258090篇 |
皮肤病学 | 26375篇 |
神经病学 | 111855篇 |
特种医学 | 48174篇 |
外国民族医学 | 366篇 |
外科学 | 184042篇 |
综合类 | 28772篇 |
现状与发展 | 1篇 |
一般理论 | 460篇 |
预防医学 | 114358篇 |
眼科学 | 28979篇 |
药学 | 98823篇 |
6篇 | |
中国医学 | 3167篇 |
肿瘤学 | 76174篇 |
出版年
2021年 | 10908篇 |
2019年 | 11631篇 |
2018年 | 16315篇 |
2017年 | 12285篇 |
2016年 | 13243篇 |
2015年 | 15190篇 |
2014年 | 20795篇 |
2013年 | 32047篇 |
2012年 | 44231篇 |
2011年 | 46882篇 |
2010年 | 27075篇 |
2009年 | 24920篇 |
2008年 | 42710篇 |
2007年 | 45049篇 |
2006年 | 45162篇 |
2005年 | 43587篇 |
2004年 | 41557篇 |
2003年 | 39492篇 |
2002年 | 38304篇 |
2001年 | 60841篇 |
2000年 | 62515篇 |
1999年 | 52277篇 |
1998年 | 14578篇 |
1997年 | 13275篇 |
1996年 | 13120篇 |
1995年 | 12457篇 |
1994年 | 11625篇 |
1993年 | 10923篇 |
1992年 | 41573篇 |
1991年 | 40764篇 |
1990年 | 39448篇 |
1989年 | 37340篇 |
1988年 | 34584篇 |
1987年 | 33699篇 |
1986年 | 32154篇 |
1985年 | 30644篇 |
1984年 | 23035篇 |
1983年 | 19591篇 |
1982年 | 11754篇 |
1979年 | 20807篇 |
1978年 | 14814篇 |
1977年 | 12064篇 |
1976年 | 11876篇 |
1975年 | 12111篇 |
1974年 | 14800篇 |
1973年 | 14474篇 |
1972年 | 13360篇 |
1971年 | 12419篇 |
1970年 | 11487篇 |
1969年 | 10410篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
992.
993.
994.
995.
996.
997.
H Gunen S S Hacievliyagil O Yetkin G Gulbas L C Mutlu E In 《The European respiratory journal》2007,29(4):660-667
The present study was designed to evaluate the hypothesis that nebulised budesonide (NB) might be an alternative to systemic corticosteroids (SC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (ECOPD). Patients hospitalised with ECOPD (n = 159) were randomised into three groups. Group 1 received only standard bronchodilator treatment (SBDT), group 2 received SC (40 mg prednisolone) plus SBDT, and group 3 received NB (1,500 microg q.i.d.) plus SBDT. Improvement during 10-day hospitalisation was compared with exacerbation and rehospitalisation rates after discharge. While mean+/-sd age was 64.1+/-8.9 yrs (female/male = 0.1), mean forced expiratory volume in one second (FEV(1)) at admission was found to be 37.2+/-12.2% predicted. Arterial blood gases and spirograms recovered faster in groups 2 and 3. While improvements in arterial oxygen tension (P(a,O(2))) and forced vital capacity (FVC) in group 2, and improvements in P(a,O(2)), FVC and FEV(1) in group 3, became significant at 24-h control, the first significant improvement in group 1 appeared in arterial oxygen saturation at 72-h control. The mean improvement of P(a,O(2)) after 10 days was 1.20 and 1.06 kPa (9 and 8 mmHg) higher in group 2 and 3, respectively, than in group 1. Blood glucose exhibited an upward trend only in group 2. The study demonstrates that nebulised budesonide may be an effective and safe alternative to systemic corticosteroids in the treatment of exacerbations of chronic obstructive pulmonary disease. 相似文献
998.
999.
C Casanova C G Cote J M Marin J P de Torres A Aguirre-Jaime R Mendez L Dordelly B R Celli 《The European respiratory journal》2007,29(3):535-540
The 6-min walking distance (6MWD) test is used in clinical practice and research into patients with chronic obstructive pulmonary disease (COPD). However, little is known about natural long-term change in this parameter. The 6MWD was measured at baseline and then annually for 5 yrs in 294 patients with COPD and its annual rate of decline was determined. Forced expiratory volume in one second (FEV1) was also measured and the relationship between changes in both markers was explored. At baseline, the median 6MWD was 380 m (range 160-600 m). It declined by 19% (16 m.yr(-1)) over the 5 yrs compared with baseline in patients with American Thoracic Society/European Respiratory Society stage III COPD (FEV1 30-50% predicted) and by 26% (15 m.yr(-1)) in patients with stage IV COPD (FEV1 <30% pred). Over the 5-yr follow-up, the proportion of patients with a minimal clinically significant decline of 54 m increased with the severity of the disease. It was 24% in stage II, 45% in stage III, and 63% in stage IV disease. In contrast, the rate of decline of FEV1 was greater in patients with milder airflow obstruction and lesser in patients with lower absolute FEV1 values. In conclusion, the 6-min walking distance test provides increasingly useful information as the severity of chronic obstructive pulmonary disease increases. 相似文献
1000.
S R Coughlin L Mawdsley J A Mugarza J P H Wilding P M A Calverley 《The European respiratory journal》2007,29(4):720-727
Obstructive sleep apnoea is associated with increased blood pressure and other features of the metabolic syndrome. The aim of the present study was to determine the relative effectiveness of continuous positive airway pressure (CPAP) in modifying these outcomes. A randomised placebo-controlled blinded crossover trial comparing cardiovascular and metabolic outcomes after 6 weeks of therapeutic and sham CPAP was performed in 34 CPAP-na?ve patients (mean+/-SD body mass and respiratory disturbance indices were 36.1+/-7.6 and 39.7+/-13.8, respectively). Mean waking systolic and diastolic blood pressure fell by 6.7 and 4.9 mmHg, respectively, when compared with sham CPAP. No change was observed in glucose, lipids, insulin resistance or the proportion of patients with metabolic syndrome. In CPAP-compliant patients the fall in blood pressure was greater and the baroreceptor sensitivity improved significantly but no metabolic variable changed. In obese Caucasians with untreated obstructive sleep apnoea, continuous positive airways pressure can improve baroreceptor responsiveness and reduce waking blood pressure within 6 weeks, but this treatment period was insufficient to modify insulin resistance or change the metabolic profile. The mechanisms underlying this difference in the time course of blood pressure and metabolic response to continuous positive airway pressure in obstructive sleep apnoea requires further exploration. 相似文献